The rebellion, which took place at the company's 18 May general meeting on annual, saw shareholders reject bonuses at the pharmaceutical firm due to concerns about disclosure and outcomes related to the company’s incentive scheme. The pay report, which is non-binding, was endorsed by the remaining 65% of shareholders. Although the pay of CEO Pascal Soriot fell from a previous £14.3m ($19.2m) to £9.4m in 2017, advisory group Institutional Shareholder Services still recommended rejecting the report, arguing that a series of high bonuses suggested the bar had been set too low by the firm.
The rebellion, which took place at the company's annual general meeting on 18 May, saw shareholders reject bonuses at the pharmaceutical firm due to concerns about disclosure and outcomes related to the company’s incentive scheme. The pay report, which is non-binding, was endorsed by the remaining 65% of shareholders. Although the pay of CEO Pascal Soriot fell from a previous £14.3m ($19.2m) to £9.4m in 2017, advisory group Institutional Shareholder Services still recommended rejecting the report, arguing that a series of high bonuses suggested the bar had been set too low by the firm.